PT-141
Bremelanotide — a synthetic melanocortin agonist developed from Melanotan II. Studied for its central nervous system mechanism of action in models of sexual motivation and arousal.
For laboratory and in vitro research purposes only. Not for human consumption.
What is PT-141?
PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide developed from Melanotan II. It acts as an agonist at melanocortin receptors — specifically MC3R and MC4R — in the central nervous system. What distinguishes it in research is its mechanism: it works centrally through the brain's dopaminergic system rather than peripherally through blood vessel dilation. The pharmaceutical form, Bremelanotide (Vyleesi), received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women.
the first cns-based compound
for desire research.
PDE5 inhibitors work by increasing peripheral blood flow. PT-141 works differently — activating the melanocortin pathway in the brain's hypothalamus to drive dopaminergic signalling. It is the only known CNS-targeted compound of its kind, and the only one in this class with FDA approval.
How PT-141 works in research models
PT-141 (Bremelanotide) is a cyclic heptapeptide that acts as an agonist at melanocortin receptors, particularly MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors which act peripherally on vascular smooth muscle, PT-141 activates the hypothalamic melanocortin pathway, producing dopaminergic signalling associated with sexual motivation.
fda approved compound class.
clinically studied.
Bremelanotide (the pharmaceutical form of PT-141) received FDA approval as Vyleesi in 2019, providing a substantial human clinical dataset. Rowan PT-141 is supplied at ≥99.0% HPLC purity with a lot-specific COA from Janoshik Analytical.
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141.
J Sex Med · 2004 · PMID: 16422953
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women.
Obstet Gynecol · 2016 · PMID: 27100321
Clinical research in published trials used subcutaneous doses of 0.75–1.75 mg. PT-141 has a half-life of approximately 2.7 hours. Reconstitute with bacteriostatic water and store at 4°C after reconstitution.
You ask, we answer.
PDE5 inhibitors like sildenafil work peripherally by increasing blood flow to genital tissue. PT-141 works centrally — activating melanocortin receptors in the brain that regulate sexual motivation and arousal — making it the only known CNS-targeted compound for this indication.
PT-141 was developed from Melanotan II with modifications to reduce its tanning and other off-target effects, while retaining its MC4R-mediated sexual response activity.
The pharmaceutical form — Bremelanotide (Vyleesi) — received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. Rowan PT-141 is a research compound for laboratory use only and is not the approved pharmaceutical product.
PT-141 has a plasma half-life of approximately 2.7 hours, as reported in clinical pharmacokinetic studies. Onset of action in clinical research was typically 45–60 minutes after subcutaneous administration.
Research Use Only
All Rowan Peptides products are intended strictly for laboratory and in vitro research purposes. They are not approved by the FDA and are not intended for human consumption, veterinary use, or any therapeutic application. By purchasing, you agree to our Terms of Service and Indemnity Waiver. Rowan Peptides LLC operates as a chemical supplier only.
Researching MC4R agonists for a project. Purity on the COA was 99.1%. Vial arrived intact. Will order again for the next phase.
Ordered this based on the melanocortin receptor research. 10mg vial, clean lyophilization, no clumping. Reconstituted smoothly. As with everything from Rowan the presentation is clean and the COA is real.
This is my second order. First one took slightly longer to ship but this one came in two days. Product is consistently good. Customer support responded same day when I had a question about reconstitution volume.
Write a Review